Phathom Pharmaceuticals (PHAT) Income towards Parent Company: 2022-2025
Historic Income towards Parent Company for Phathom Pharmaceuticals (PHAT) over the last 4 years, with Sep 2025 value amounting to -$30.0 million.
- Phathom Pharmaceuticals' Income towards Parent Company rose 64.98% to -$30.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$274.4 million, marking a year-over-year increase of 19.14%. This contributed to the annual value of -$334.3 million for FY2024, which is 65.99% down from last year.
- Latest data reveals that Phathom Pharmaceuticals reported Income towards Parent Company of -$30.0 million as of Q3 2025, which was up 60.39% from -$75.7 million recorded in Q2 2025.
- Phathom Pharmaceuticals' 5-year Income towards Parent Company high stood at -$30.0 million for Q3 2025, and its period low was -$94.3 million during Q1 2025.
- For the 3-year period, Phathom Pharmaceuticals' Income towards Parent Company averaged around -$66.9 million, with its median value being -$75.7 million (2025).
- In the last 5 years, Phathom Pharmaceuticals' Income towards Parent Company tumbled by 123.20% in 2024 and then spiked by 64.98% in 2025.
- Phathom Pharmaceuticals' Income towards Parent Company (Quarterly) stood at -$55.0 million in 2022, then plummeted by 44.76% to -$79.6 million in 2023, then rose by 6.36% to -$74.5 million in 2024, then soared by 64.98% to -$30.0 million in 2025.
- Its Income towards Parent Company was -$30.0 million in Q3 2025, compared to -$75.7 million in Q2 2025 and -$94.3 million in Q1 2025.